Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical ...

Neuromodulation is an adjunct to medication for Parkinson’s symptom management, with growing interest in whether it could one day contribute to disease-modifying therapies.

Discover why Indian women are ditching costly ₹15,000 PRP facials for affordable at-home PDRN serums, and how this skincare ...

A BMW M3 takes over an open space and turns it into a playground for drifting, pushing the car to its limits with aggressive ...

SetPoint Medical, a medical technology company dedicated to improving care for people living with chronic autoimmune diseases, today announced that it has initiated enrollment in the pilot clinical ...

MA’s ZEPHYR Phase 2 trial in schizophrenia ; Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorder; Topline ...

More rigorous randomized data are needed, which could be challenging in light of the drugs’ indication based on BMI.

Replicating the brain's capabilities, an impossible task, may theoretically require thousands of H100, one of NVIDIA's most ...

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy followin ...

MicroAlgo Inc. (the "Company" or "MicroAlgo") (NASDAQ: MLGO), today announced the proposal of a new approach to solving the Boolean function query problem. This framework starts from the ...

The transition between wakefulness and states of reduced consciousness, whether pharmacologically induced via anesthesia or pathologically necessitated by ...

Functional gastrointestinal disorders (FGIDs), including irritable bowel syndrome, functional dyspepsia, and chronic visceral pain syndromes, affect a ...